Equities Analysts Issue Forecasts for TARS Q3 Earnings

Key Points

• William Blair forecasts Tarsus Pharmaceuticals to post a Q3 2025 EPS of ($0.38), with a full-year estimate of ($3.17) per share.
• Tarsus Pharmaceuticals reported Q2 earnings of ($0.48) per share, missing the consensus estimate by ($0.15), despite exceeding revenue expectations with $102.66 million.
• Institutional investors own 90.01% of Tarsus Pharmaceuticals, indicating strong support from hedge funds and other large investors.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities research analysts at William Blair issued their Q3 2025 EPS estimates for Tarsus Pharmaceuticals in a note issued to investors on Wednesday, August 6th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings of ($0.38) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals' Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($1.46) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at $0.23 EPS, Q3 2026 earnings at $0.40 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $1.39 EPS.

A number of other research analysts have also recently weighed in on the stock. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target on the stock. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price on the stock in a research report on Tuesday, May 27th. Finally, Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Trading Up 2.1%

TARS stock traded up $1.06 during midday trading on Monday, reaching $52.42. 504,136 shares of the company's stock traded hands, compared to its average volume of 660,621. The company has a market capitalization of $2.21 billion, a P/E ratio of -22.50 and a beta of 0.79. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. Tarsus Pharmaceuticals has a fifty-two week low of $24.95 and a fifty-two week high of $57.28. The business has a 50-day moving average price of $41.82 and a two-hundred day moving average price of $45.71.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). The business had revenue of $102.66 million for the quarter, compared to analyst estimates of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently modified their holdings of TARS. Geode Capital Management LLC lifted its holdings in Tarsus Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 838,804 shares of the company's stock worth $46,456,000 after purchasing an additional 3,014 shares during the period. Wells Fargo & Company MN lifted its holdings in Tarsus Pharmaceuticals by 44.1% in the fourth quarter. Wells Fargo & Company MN now owns 57,004 shares of the company's stock worth $3,156,000 after purchasing an additional 17,451 shares during the period. Federated Hermes Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $4,303,000. Invesco Ltd. lifted its holdings in Tarsus Pharmaceuticals by 36.7% in the fourth quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after purchasing an additional 250,018 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $1,107,000. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.